Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (4461)	8/11/2001 8:30:13 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 52153

ICOS doing anything with their PDE5 inhibitor? They may be crawling all over such anecdote, as they have the first generation ETA receptor in trials for PH (for which the Actelion results might be read as a positive). So..... I agree with your logic, but timing might dictate that Cialis would steal the show? Interesting.

To: rkrw who wrote (4461)	8/11/2001 8:54:30 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 52153

<<The actelion drug swept the vote 10-0, how does it compare with the uthr drug? If both are approved, which is the winner in your opinion? >> Tracleer is viewed as first line therapy (stage II, into stage III), and it is not without problems. Elevated liver enzymes. UTHR candidate Remodulin is for more advanced PAH (stage III $ IV) and it is viewed as Flolan substitution. This two drug will not compete very directly, however I will not consider UTHR based on Remodulin, at any price. Miljenko